The Globe and Mail: Generic forms of semaglutide, the active ingredient in Ozempic, have begun to hit pharmacy shelves. The first product widely available is from Toronto-headquartered Apotex Inc., which is pricing its version of Ozempic at less than a third of the cost of the brand name.
Meanwhile, Danish drug manufacturer Novo Nordisk NVO-N, the maker of Ozempic,announced Tuesday it would start offering discounts to patients not covered by insurance so they could pay the generic price for the brand-name product…